Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorHintz, Mandy
dc.contributor.authorPopp, Ilinca
dc.contributor.authorBilger, Angelika
dc.contributor.authorGrosu, Anca L.
dc.date.accessioned2021-04-15T13:14:41Z
dc.date.available2021-04-15T13:14:41Z
dc.date.issued2020-03-04
dc.description.abstractAim - The aim of this study was to characterize the survival results of patients with up to four brain metastases after intense local therapy (primary surgery or stereotactic radiotherapy) if extracranial metastases were absent or limited to one site, e.g. the lungs.<p> <p>Background - Oligometastatic disease has repeatedly been reported to convey a favorable prognosis.<p> <p>Material and methods - This retrospective study included 198 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status and other variables was collected. Uni- and multivariate tests were performed.<p> <p>Results - Median survival was 16.5 months (single brain metastasis) and 9.8 months (2–4, comparable survival for 2, 3 and 4), respectively (p = 0.001). After 5 years, 15 and 2% of the patients were still alive. In patients alive after 2 years, added median survival was 23 months and the probability of being alive 5 years after treatment was 26%. In multivariate analysis, extracranial metastases were not significantly associated with survival, while primary tumor control was.<p> <p>Conclusion - Long-term survival beyond 5 years is possible in a minority of patients with oligometastatic brain disease, in particular those with a single brain metastasis. The presence of extracranial metastases to one site should not be regarded a barrier towards maximum brain-directed therapy.en_US
dc.descriptionAccepted manuscript version, licensed <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0. </a>en_US
dc.identifier.citationNieder C, Hintz M, Popp I, Bilger A, Grosu AL. Long-term survival results after treatment for oligometastatic brain disease. Reports of Practical Oncology and Radiotherapy. 2020;25(3):307-311en_US
dc.identifier.cristinIDFRIDAID 1813253
dc.identifier.doi10.1016/j.rpor.2020.03.001
dc.identifier.issn1507-1367
dc.identifier.issn2083-4640
dc.identifier.urihttps://hdl.handle.net/10037/20893
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalReports of Practical Oncology and Radiotherapy
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleLong-term survival results after treatment for oligometastatic brain diseaseen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record